Trump Administration Betrays Pro-Life Promises by Failing to Regulate Dangerous Abortion Drug Mifepristone

Source: Jordan Boyd. "Trump Admin Claimed To Be Pro-Life, But Won't Regulate Mifepristone." February 24, 2026. thefederalist.com

The Gist

The author argues that Trump promised to be pro-life but is breaking that promise by refusing to crack down on a dangerous abortion pill. Women are getting hurt, states can't enforce their laws, and pro-life voters are getting fed up with empty promises.

Conclusion

The Trump administration is failing to fulfill its pro-life promises by refusing to regulate mifepristone, thereby endangering women and undermining states' abortion laws

Premises

  1. Mifepristone is demonstrably dangerous to women, with studies showing serious adverse events occur in more than 1 in 10 women who take it
  2. The Trump administration promised to review and regulate mifepristone but has taken no meaningful action despite being in office for over a year
  3. The FDA is deliberately stalling by claiming to conduct a safety study while not actually reviewing any data
  4. Biden-era mail-order abortion expansions allow dangerous unsupervised use of mifepristone and undermine state abortion laws
  5. Pro-life voters (32% of Republicans) are threatening to abandon the party if leaders weaken pro-life policies
  6. States cannot effectively enforce their abortion laws because federal mail-order schemes circumvent state sovereignty
  7. The FDA could immediately reinstate Trump's first-term safety protocols without waiting for any study

Assumptions

View this argument on LogicFirst.ai